Journal · Tirzepatide · Evidence

Do tirzepatide tablets actually work?

This site’s name asks the market’s most-searched question, so we owe it the straightest possible answer: there is no FDA-approved tirzepatide tablet, the sublingual and ODT versions sold today have no published human absorption data, and the real GLP-1 pills arriving now are different molecules entirely. Here is the full evidence picture.

Start with what tirzepatide is made of

Tirzepatide is a peptide — a chain of thirty-nine amino acids with a fatty-acid tail. That single fact explains almost everything about why it is sold as a once-weekly injection and why a genuine tirzepatide tablet is so hard to make. Your digestive tract exists to destroy peptides: stomach acid denatures them, and proteases in the stomach and small intestine chop them into amino acids, exactly as they would a bite of chicken. What survives digestion still has to cross the intestinal wall, which admits large molecules grudgingly. Swallow a naked peptide and the fraction reaching your bloodstream rounds to zero.

Injection skips the entire battlefield, which is why every approved form of tirzepatide — Mounjaro and Zepbound alike — is subcutaneous. Any company selling you “tirzepatide tablets” is therefore claiming to have solved a problem that one of the world’s largest pharmaceutical companies, with every incentive to sell a pill, has not solved for this molecule. That claim deserves evidence, not vibes. So let’s look at the three places evidence actually exists.

Lesson one: Rybelsus, the peptide pill that barely works on purpose

There is exactly one oral peptide GLP-1 on the market, and its engineering tells you the price of admission. Rybelsus is oral semaglutide co-formulated with SNAC, an absorption enhancer that creates a tiny high-pH bubble against the stomach wall and shepherds a sliver of drug across. Even with that technology, oral semaglutide’s bioavailability is on the order of one percent, which is why the tablet doses are 3, 7, and 14 milligrams to replicate injections measured in fractions of a milligram — and why the label demands it be taken fasting, with no more than four ounces of water, thirty minutes before anything else, because a sip of coffee collapses the absorption. Rybelsus is a triumph of formulation science, and it is also the proof of how narrow the corridor is: a purpose-built enhancer, a hundred-fold dose premium, and monastic dosing rules, all to get one peptide across the gut.

Novo Nordisk pushed the same technology further for obesity: in the OASIS 1 trial, oral semaglutide at 50 mg daily produced roughly 15% weight loss at 68 weeks — injectable-class results from a tablet — and a 25 mg oral dose for weight management reached the FDA’s desk in 2025. Check the current approval status the week you read this, because it was in motion at our last verification; either way, oral semaglutide is a real, trial-documented product line. Note what it required: SNAC, gram-scale annual API quantities, and a decade of pharmacokinetic work.

Lesson two: the real GLP-1 pill is not a peptide at all

The other credible tablet takes the opposite route. Orforglipron, Lilly’s once-daily pill, is not a peptide — it is a small molecule that activates the GLP-1 receptor while being small and sturdy enough to survive digestion like an ordinary drug, with no food or water restrictions. In the ATTAIN-1 phase 3 results reported in 2025, the highest dose averaged roughly 12% weight loss at 72 weeks, with the familiar GI side-effect profile, and Lilly moved toward regulatory submission on an aggressive timeline. Orforglipron is weaker than injectable tirzepatide — about twelve percent versus about twenty — but it is a genuine pill with phase-3 evidence, and when it launches it will define what “GLP-1 tablet” legitimately means. Notice, though, what it is not: it is not tirzepatide. There is no oral tirzepatide in Lilly’s public pipeline, because the dual GIP/GLP-1 peptide has no SNAC-style oral program behind it. As of our last verification, a true tirzepatide tablet does not exist at any stage of published human testing.

So what is being sold as a “tirzepatide tablet” today?

Compounded sublingual drops, troches, or orally-disintegrating tablets (ODTs): tirzepatide suspended in a base that dissolves under the tongue, on the theory that the drug will absorb through the oral mucosa and skip the stomach entirely. The theory is not absurd — some small drugs absorb sublingually very well. But tirzepatide is not a small drug, oral-mucosal absorption falls off steeply with molecular size, and here is the part that matters most: as of this writing we can find no published human pharmacokinetic study — no blood-level data — for sublingual or ODT tirzepatide from any compounder, and none for sublingual semaglutide either. Not weak data. No data. What exists instead are seller-run before/after weight surveys without controls, which cannot distinguish drug effect from the diet changes, expectation effects, and selection bias that come free with every weight-loss program.

That does not prove the products deliver nothing; low single-digit absorption of a potent drug could still be biologically active, and a few compounders claim proprietary enhancers. It proves the burden of proof is unmet. Injectable tirzepatide earned its 20% figure across tens of thousands of trial participants with measured blood levels. A dissolving tablet of the same molecule inherits none of that evidence, because route of administration is not a detail — it is the difference between a drug and a lozenge.

The questions that separate a real product from a costume

If you are considering an ODT or sublingual protocol from any seller — including NexLife, whose ODT plans are priced on our provider file and whose commercial relationship with this site is disclosed here — put five questions to the prescriber, in writing. Ask whether human blood-level data exists for this exact formulation, and where it is published. Ask what the assumed sublingual bioavailability is and how the dose was chosen to compensate. Ask which pharmacy compounds it, and for the third-party potency and sterility testing on the current batch. Ask what objective marker will be tracked — weight alone, or labs — and at what point a non-response means stopping. And ask why the prescriber recommends this route over the injectable that carries the actual trial evidence, at a time when injectable prices have fallen. Good-faith sellers will answer all five without flinching. Evasion on the first two is your answer.

The honest bottom line, buyer by buyer

If your goal is the results in the trials, the evidence points one way: injectable tirzepatide is the form that produced them, injectable semaglutide is the runner-up with the deepest safety record, and needle aversion is better solved with autoinjector pens and 4 mm needles than with an unproven route. If you specifically want a pill, the legitimate paths are oral semaglutide — Rybelsus now, the higher-dose obesity tablet as it clears approval — and orforglipron when it launches; both carry published human data, which is the entire point. And if you are drawn to a compounded sublingual or ODT anyway — for swallowing difficulties, needle phobia that pens don’t fix, or curiosity — go in with eyes open: you are the trial, no one is collecting the data, and you should pay accordingly, month to month, never a prepaid year. We will update this review the day any compounder publishes real pharmacokinetics, and the changelog will record the change.

Frequently asked questions

Sources

• Rybelsus (oral semaglutide) prescribing information, including SNAC co-formulation and administration requirements. U.S. FDA label.
• Knop FK, et al. Oral semaglutide 50 mg for overweight and obesity (OASIS 1). The Lancet, 2023.
• Eli Lilly. ATTAIN-1 phase 3 topline results for orforglipron in obesity, 2025; ACHIEVE-1 in type 2 diabetes, 2025.
• Jastreboff AM, et al. SURMOUNT-1. New England Journal of Medicine, 2022 — the injectable benchmark any oral form must be compared against.
• Reviews of oral peptide delivery and SNAC-mediated absorption (bioavailability on the order of ~1%).

Editor’s note: verify every citation against PubMed and fda.gov, and re-check the oral semaglutide 25 mg approval status and orforglipron submission status, before publication.